# F. Graf Finckenstein

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/f-graf-finckenstein/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,565 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 6 |
| i10-index | 4 |
| Last Known Institution | Theravance Biopharma (United States) |
| OpenAlex ID | https://openalex.org/A5107834331 |
| Works | 12 |

## Researcher papers

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Growth Hormone and Insulin-like Growth Factors](https://scholariq.org/topics/growth-hormone-and-insulin-like-growth-factors/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.